Table 3.
Variable Means or Frequencies, by Medication Class (Nonelderly Adults)
| Statins (no dx) | Diabetes (no dx) | Hypertension (with dx) | Seizure Disorder(with dx) | Antipsychotic (with dx) | Antidepressant(with dx) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | NC | GA | NC | GA | NC | GA | NC | GA | NC | GA | NC | GA |
| Individual characteristics (% of individuals) | ||||||||||||
| Age | 52.6 | 52.6 | 50.8 | 50.8 | 50.4 | 49.4 | 41.9 | 39.8 | 42.7 | 41.3 | 41.9 | 41.8 |
| (9.1) | (9.1) | (10.1) | (10.1) | (10.2) | (10.3) | (12.3) | (12.5) | (11.3) | (11.1) | (11.4) | (11.4) | |
| Male | 35.0 | 31.2 | 29.7 | 24.6 | 32.7 | 27.3 | 46.9 | 43.6 | 48.4 | 42.5 | 20.9 | 17.8 |
| White (%) | 53.6 | 48.7 | 40.2 | 35.5 | 37.3 | 30.1 | 51.8 | 47.2 | 49.3 | 36.9 | 66.8 | 56.2 |
| African American | 30.1 | 36.3 | 44.3 | 50.7 | 47.9 | 57.4 | 36.0 | 43.4 | 38.9 | 52.1 | 20.2 | 32.7 |
| Other race | 16.3 | 15.0 | 15.5 | 13.7 | 14.9 | 12.5 | 12.1 | 9.5 | 11.8 | 11.0 | 13.3 | 11.1 |
| Latino/a | 0.5 | 0.4 | 0.8 | 0.4 | 0.4 | 0.2 | 0.4 | 0.3 | 0.4 | 0.3 | 0.6 | 0.2 |
| Continuously enrolled (%) | 72.1 | 71.7 | 67.6 | 68.3 | 68.0 | 67.1 | 74.0 | 74.6 | 78.8 | 79.8 | 61.5 | 62.0 |
| Number of diagnoses other than target condition | 5.8 | 3.9 | 5.8 | 4.0 | 5.9 | 4.6 | 6.5 | 5.2 | 6.1 | 4.5 | 7.0 | 5.5 |
| Received long prescription in prepolicy period (%) | 28.7 | — | 31.9 | — | 36.8 | — | 31.3 | — | 21.5 | — | 26.6 | — |
| Used only generic medications (%) | 3.0 | — | 4.8 | — | 18.4 | — | 12.0 | — | 9.9 | — | 4.2 | — |
| Outcome measures (person-quarter means) | ||||||||||||
| Proportion of days covered (PDC) | 0.77 | 0.78 | 0.79 | 0.79 | 0.82 | 0.79 | 0.83 | 0.82 | 0.82 | 0.79 | 0.74 | 0.73 |
| (0.23) | (0.24) | (0.23) | (0.24) | (0.22) | (0.23) | (0.21) | (0.22) | (0.22) | (0.23) | (0.25) | (0.25) | |
| Median PDC | 0.87 | 0.88 | 0.90 | 0.89 | 0.92 | 0.90 | 0.93 | 0.92 | 0.92 | 0.89 | 0.83 | 0.81 |
| PDC>0.80 (%) | 59.4 | 60.6 | 63.0 | 61.3 | 67.1 | 62.8 | 69.7 | 67.6 | 68.2 | 62.2 | 53.3 | 51.3 |
| Target medication expenditures | 169 | 157 | 189 | 166 | 128 | 120 | 308 | 287 | 710 | 586 | 188 | 169 |
| (127) | (128) | (218) | (177) | (141) | (118) | (480) | (420) | (759) | (609) | (208) | (174) | |
| Total expenditures | 2,193 | 2,015 | 2,238 | 2,031 | 2,063 | 2,031 | 2,640 | 2,396 | 2,815 | 2,193 | 2,456 | 2,273 |
| (3,605) | (3,609) | (3,750) | (4,930) | (3,946) | (4,720) | (4,634) | (4,440) | (3,627) | (3,231) | (4,038) | (4,148) | |
| Total observations | 255,281 | 161,666 | 256,601 | 175,267 | 618,927 | 355,910 | 130,186 | 87,066 | 150,260 | 116,095 | 268,529 | 139,960 |
| Unique individuals | 24,618 | 15,673 | 25,654 | 17,553 | 61,544 | 35,685 | 12,442 | 8,307 | 13,863 | 10,693 | 27,580 | 14,438 |